Fruzaqla™ (fruquintinib)

November 10, 2023

Fruzaqla™ (fruquintinib)


FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)

Louisville, KY — November 10, 2023 — Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Takeda for Fruzaqla™ (fruquintinib). Fruzaqla™, is an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type (WT) and medically appropriate, an anti-EGFR therapy. Fruzaqla™ is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status. Fruzaqla™ is a selective oral inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, which play a pivotal role in blocking tumor angiogenesis.

“Onco360 is excited to partner with the team at Takeda for another opportunity and become a specialty pharmacy provider for Fruzaqla,” said Benito Fernandez, Chief Commercial Officer. “We are pleased to add this unique treatment option for adult patients with metastatic colorectal cancer to our portfolio of oncology products; we remain committed to our mission of improving the lives of patients and their caregivers batting cancer, rare and orphan diseases.”

The National Cancer Institute estimates 153,020 new cases of CRC will be diagnosed in 2023, representing 7.8% of all new cancer cases, in the U.S.1 Approximately 70% of patients with CRC will experience metastatic disease, whether at diagnosis or after treatment. Metastases are the main cause of CRC-related mortality. Colorectal cancer is the fourth most frequent diagnosed cancer and second leading cause of death in the U.S.

The approval of Fruzaqla™ is based on data from two large Phase 3 trials: the multi-regional FRESCO-2 trial, data from which were published in the Lancet2, along with the FRESCO trial conducted in China, data from which were published in JAMA.3 The trials investigated Fruzaqla™ plus best supportive care versus placebo plus best supportive care in patients with previously treated mCRC. Both FRESCO and FRESCO-2 met their primary and key secondary efficacy endpoints and showed consistent benefit among a total of 734 patients treated with Fruzaqla™. The safety profile for Fruzaqla™ was consistent across the trials. Fruzaqla™ is the first novel chemotherapy free agent approved in more than a decade.

Please see the full Prescribing Information for FRUZAQLA™ or visit www.fruzaqla.com.


# # #

Media Contact:

Benito Fernandez, Chief Commercial Officer
[email protected]



  1. National Cancer Institute. Cancer Stat Facts: Colorectal cancer. Accessed November 2023. https://seer.cancer.gov/statfacts/html/colorect.html
  2. Dasari, A, et al. Fruquintinib vs Placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicenter, randomized double blind, phase 3 study. Lancet. 2023; 402, 41-53
  3. Li, J, et al. Effect of fruquintinib vs Placebo on overall survival in patients with previously
    treated metastatic colorectal cancer. FRESCO trial. JAMA. 2018; 319(24):2486-2496.



FRUZAQLA is a trademark of HUTCHMED Group Enterprises Limited, used under license. TAKEDA® and the TAKEDA Logo are registered trademarks of TAKEDA Pharmaceutical Company Limited. Copyright 2023 Takeda Pharmaceuticals U.S.A., inc. All rights reserved.